Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kyverna Therapeutics, Inc. - Common Stock (NQ: KYTX )

3.960 +0.040 (+1.02%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 117,486
Open 3.900
Bid (Size) 3.750 (1)
Ask (Size) 4.050 (3)
Prev. Close 3.920
Today's Range 3.730 - 3.980
52wk Range 3.625 - 35.06
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Investor Reminder (KYTX): Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors of February 7, 2025 Deadline
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures Financial Legal Securities Market
KYVERNA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Kyverna Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
-86.80%
-86.80%
1 Month
-22.50%
-22.50%
3 Month
-24.43%
-24.43%
6 Month
-45.53%
-45.53%
1 Year
-86.80%
-86.80%

More News

Read More
KYTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
KYVERNA THERAPEUTICS, INC. (NASDAQ: KYTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Kyverna Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
KYTX Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors of Securities Fraud Class Action Lawsuit Deadline
Via NewMediaWire
Topics Fraud Initial Public Offering Lawsuit
Exposures Financial Legal Securities Market
CLASS ACTION NOTICE FOR KYTX: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Losses to Contact the Firm
Via NewMediaWire
Topics Fraud Initial Public Offering Lawsuit
Exposures Financial Legal Securities Market
CLASS ACTION NOTICE FOR KYTX: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud Initial Public Offering Lawsuit
Exposures Financial Legal Securities Market
KYTX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Kyverna Therapeutics, Inc. - Contact Kessler Topaz Meltzer & Check, LLP
From Kessler Topaz Meltzer & Check LLP
Via GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kyverna Therapeutics, Inc. (KYTX)
From Glancy Prongay & Murray LLP
Via Business Wire
KYTX Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc.
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kyverna Therapeutics, Inc. (KYTX)
From Law Offices of Howard G. Smith
Via Business Wire
KYVERNA THERAPEUTICS, INC. (NASDAQ: KYTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Kyverna Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
KYVERNA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Kyverna Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc. (KYTX) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Lost Money on Kyverna Therapeutics, Inc.(KYTX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Via ACCESSWIRE
Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - KYTX
Via ACCESSWIRE
Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX) Seeking Recovery for Investors – Contact Levi & Korsinsky
Via ACCESSWIRE
February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against KYTX
Via ACCESSWIRE
The Schall Law Firm Urges Stockholder Participation In A Securities Fraud Case Against Kyverna Therapeutics Inc
Via ACCESSWIRE
Investors in Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX
Via ACCESSWIRE
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc. (KYTX) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX
Via ACCESSWIRE
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX
Via ACCESSWIRE
KYTX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.